Join to View Full Profile
17 Timber LnRandolph, NJ 07869
Phone+1 973-989-5695
Dr. Reinhart is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Detroit Medical Center/Wayne State UniversityFellowship, Infectious Disease, 1986 - 1987
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1981 - 1984
University of Wurzburg Faculty of MedicineClass of 1978
Certifications & Licensure
MI State Medical License 1986 - 2026
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 105 citationsEfficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus comp...Keith S Kaye, Andrew F Shorr, Richard G Wunderink, Bin Du, Gabrielle E Poirier
The Lancet. Infectious Diseases. 2023-09-01 - 27 citationsIn vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in ChinaQiwen Yang, Yingchun Xu, Peiyao Jia, Ying Zhu, Jingjia Zhang
The Journal of Antimicrobial Chemotherapy. 2020-07-01 - 23 citationsAntimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Anti...Cecilia G Carvalhaes, Michael D. Huband, Harald H Reinhart, Robert K. Flamm, Helio S. Sader
Antimicrobial Agents and Chemotherapy. 2019-02-26
Press Mentions
Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in CIDPNovember 16th, 2021
Zai Lab and Crescendo Biologics Enter Exclusive Worldwide License Agreement for Innovative Protein Therapeutics for Inflammatory IndicationsMay 30th, 2018- Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 as a Topical Treatment for Chronic Plaque PsoriasisMay 25th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
